Today: heartbreakingly, not one drug can prevent, cure or permanently reverse symptoms of Alzheimer’s disease, which currently affects 5 million Americans.
In the future: imagine a world without Alzheimer’s - a world in which therapeutic drugs protect those of us prone to the disease long before symptoms emerge.
JAXtaposition: Scientists at The Jackson Laboratory (JAX) are harnessing powerful genomic technologies to identify biological markers of Alzheimer’s disease. It’s a bold approach, aiming to identify people at risk for Alzheimer’s disease years before symptoms emerge.
This is the future of medicine. This is JAXtaposition.
Gregory Carter, Ph.D.
The Jackson Laboratory
Gregory Carter received his Ph.D. in Theoretical Physics from the University of Minnesota, and held postdoctoral positions at the Niels Bohr Institute, Stony Brook University, and the University of Washington. Drawn by the promise of data-driven biomedicine, Greg transitioned to the Institute for Systems Biology in 2003 to apply mathematical modeling approaches to genomic analysis. He joined The Jackson Laboratory faculty in 2010, where he develops new analytical frameworks to determine how multiple genetic and environmental factors interact to cause Alzheimer’s disease, metabolic disorders, and autoimmune diseases. He currently leads a multi-institutional computational biology team in the Model Organism Development and Evaluation for Alzheimer’s Disease (MODEL-AD) consortium, involving scientists at JAX, Indiana University, and Sage Bionetworks.